

Jonathan Corren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/455179/publications.pdf>

Version: 2024-02-01

46
papers

3,166
citations

279487

23
h-index

253896

43
g-index

46
all docs

46
docs citations

46
times ranked

2847
citing authors

#	ARTICLE	IF	CITATIONS
1	Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β_2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. <i>Lancet</i> , The, 2016, 388, 31-44.	6.3	760
2	Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 595-605.	1.5	380
3	Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma. <i>Chest</i> , 2016, 150, 799-810.	0.4	337
4	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq0 0 0 rgBT /Overlock 10 recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1023-1042.	2.7	232
5	EAACI Biologicals Guidelinesâ€™ Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 14-44.	2.7	156
6	TSLP: from allergy to cancer. <i>Nature Immunology</i> , 2019, 20, 1603-1609.	7.0	132
7	Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 516-526.	2.0	123
8	COVID-19, asthma, and biological therapies: What we need to know. <i>World Allergy Organization Journal</i> , 2020, 13, 100126.	1.6	90
9	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines â€™ recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1043-1057.	2.7	85
10	Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 47-58.	5.2	74
11	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelinesâ€™ Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1058-1068.	2.7	67
12	New Targeted Therapies for Uncontrolled Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1394-1403.	2.0	59
13	Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 957-965.e3.	1.5	58
14	Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 122, 41-49.e2.	0.5	50
15	Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1786-1796.	2.7	49
16	Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 527-539.e9.	2.0	45
17	Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. <i>ERJ Open Research</i> , 2019, 5, 00009-2019.	1.1	36
18	Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. <i>ERJ Open Research</i> , 2020, 6, 00204-2019.	1.1	36

#	ARTICLE	IF	CITATIONS
19	Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 91-99.	1.5	34
20	Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 187-193.	0.5	32
21	Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 101-115.	3.3	32
22	Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1212-1223.e6.	2.0	31
23	Asthma Yardstick. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 133-142.e3.	0.5	26
24	Dupilumab is effective in type 2â€high asthma patients receiving highâ€dose inhaled corticosteroids at baseline. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 269-280.	2.7	25
25	Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1045-1063.	1.5	25
26	Optimum Treatment of Rhinitis in the Elderly. <i>Drugs and Aging</i> , 1995, 7, 168-175.	1.3	24
27	Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4334-4342.e6.	2.0	23
28	Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1-11.	1.5	21
29	Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 410-419.	2.0	21
30	A Comprehensive Analysis of the Stability of Blood Eosinophil Levels. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1978-1987.	1.5	19
31	Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 222-224.e1.	0.5	14
32	<p>Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 701-711.	1.5	14
33	The effect of tezepelumab on hospitalizations and emergency department visits in patients with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 211-214.	0.5	12
34	Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. <i>European Respiratory Journal</i> , 2021, 58, 2004498.	3.1	9
35	Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUSâ€24 and SINUSâ€52 trials. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 1191-1195.	1.5	9
36	Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2018, 34, 65-80.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Biomarkers of Type 2 Airway Inflammation in Airway Disease: And Then There Were Two. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2640-2642.	2.0	4
38	Inflammatory Disorders Associated with Allergy. Immunology and Allergy Clinics of North America, 2017, 37, 233-246.	0.7	3
39	Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform®) for the treatment of asthma. Drug Design, Development and Therapy, 2014, 8, 1555.	2.0	2
40	Burden of Persistent Asthma in Patients Treated With Medium- to High-Dose Inhaled Corticosteroids: Baseline Data From a Phase 2 Clinical Trial of Dupilumab. Chest, 2015, 148, 4A.	0.4	2
41	Advancing the Care of Severe Asthma: Differential Diagnosis, Multidisciplinary Management, and Patient Engagement. American Journal of Medicine, 2019, , .	0.6	2
42	Reply. Journal of Allergy and Clinical Immunology, 2021, 147, 413-414.	1.5	2
43	A real-world study of ICS use in patients with severe eosinophilic asthma treated with mepolizumab. Annals of Allergy, Asthma and Immunology, 2021, , .	0.5	2
44	Evaluation and treatment of asthma: an overview. American Journal of Managed Care, 2005, 11, S408-15; quiz S427-33.	0.8	2
45	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 822.	2.0	0
46	Bronchodilator Responsiveness: An Underappreciated Biomarker for Asthma Exacerbations. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 229-230.	2.0	0